Biogen reported first-quarter profit that topped estimates as the company’s cost-cutting efforts took hold and sales of its closely watched Alzheimer’s drug, Leqembi, came in higher than expected.
Comments are closed.
April 24, 2024 - 14:51 By Pharos Investment Advisors Comments are Off "Corporate", $Biogen, Biotech and Pharma
Biogen reported first-quarter profit that topped estimates as the company’s cost-cutting efforts took hold and sales of its closely watched Alzheimer’s drug, Leqembi, came in higher than expected.
Comments are closed.
Regulated by Hellenic Capital Market Commission
with Registration Number 5/700/10.12.2014
Copyright 2023©. All Rights Reserved